SCHEMBL16006559

SCHEMBL16006559

CS(=O)(=O)Nc1noc2c(Br)cccc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.38
KAT8 Q9H7Z6 2/20 0.36
KAT7 O95251 1/20 0.36
KAT6B Q8WYB5 1/20 0.36
KAT6A Q92794 1/20 0.36
KAT5 Q92993 1/20 0.36
EDNRA P25101 4/20 0.36
EDNRB P24530 3/20 0.36
SCN9A Q15858 4/20 0.36
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
BRD4 O60885 1/20 0.34
EP300 Q09472 1/20 0.33
KAT2B Q92831 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16006437 0.83 SMN1; SMN2 (0.46) KEAP1KAT8EDNRAEDNRBSCN9A
SCHEMBL16158008 0.81 SCN9A (0.40) KEAP1KAT8KAT7KAT6BKAT6A
SCHEMBL25639241 0.79 L3MBTL1 (0.46) KEAP1SCN9AKMT2AKDM4EHPGD
SCHEMBL24249760 0.79 EPHX2 (0.42) KEAP1KAT6AEDNRAEDNRBSCN9A
SCHEMBL21609155 0.77 SCN9A (0.46) KEAP1KAT8KAT7KAT6BKAT6A
SCHEMBL29268181 0.74 KMT2A (0.56) KAT8KAT6ASCN9AKMT2AEP300
SCHEMBL16006540 0.74 CA12 (0.35) KEAP1KAT8KAT7KAT6BKAT6A
SCHEMBL21438291 0.74 SMN1; SMN2 (0.40) KMT2AKDM4EHPGDHSD17B10
SCHEMBL21609045 0.71 KAT6A (0.56) KAT8KAT7KAT6BKAT6AKAT5
SCHEMBL29652401 0.71 KAT6A (0.56) KAT8KAT7KAT6BKAT6AKAT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3954679-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS Gilead Sciences, Inc. (US) 2022-02-16 EP disclosed
EP-3409667-B1 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS GILEAD SCIENCES INC (US) 2021-07-21 EP disclosed
EP-2961742-B1 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2018-08-01 EP disclosed
US-9951043-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2018-04-24 US disclosed
US-20160108030-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-04-21 US disclosed
US-20160108030-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-04-21 US disclosed
US-20140303164-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2014-10-09 US disclosed
US-20140303164-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2014-10-09 US disclosed
WO-2014134566-A2 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108030-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, RPL35 KEAP1 2233/4885KAT8 3428/4885KAT7 2527/4885
US-20140303164-A1 THERAPEUTIC COMPOUNDS HAVCR2, SARS1, G6PD KEAP1 2091/4885KAT8 3670/4885KAT7 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.